美国肝硬化住院患者急性肾损伤(含肝肾综合征)的发病率与结局
该回顾性队列研究纳入美国11个医院网络2019年连续收治的2063例肝硬化合并急性肾损伤(AKI)成人患者,按预设定义判定AKI病因。肾前性AKI最常见(44.3%),其次为急性肾小管坏死(ATN,30.4%)和肝肾综合征(HRS-AKI,12.1%)。90天死亡率以肾前性AKI最低(22.2%),HRS-AKI与ATN相近(49.0% vs 52.7%)。
要点
- 肝硬化住院患者AKI最常见病因为肾前性(44.3%),其次ATN(30.4%)和HRS-AKI(12.1%)。
- 以肾前性AKI为参照,HRS-AKI的90天死亡校正sHR为2.78,ATN为2.83。
- HRS-AKI与ATN的90天死亡率相近(49.0% vs 52.7%,p=0.42),均约50%。
核心结论
- AKI是肝硬化的严重并发症,HRS-AKI不常见且结局与ATN相似。
- AKI病因、AKI分期/严重程度及治疗未完全应答与死亡率相关。
- 需要进一步优化HRS-AKI的血管收缩剂治疗和ATN的支持治疗。
研究设计与样本
- 回顾性队列研究,纳入美国11个医院网络2019年连续收治的肝硬化合并AKI成人患者2063例。
- AKI病因依据预设临床定义判定为肾前性/低血容量性AKI、HRS-AKI、ATN或其他。
主要发现
- 患者中位年龄62岁(IQR 54-69),女性38.3%,中位MELD-Na评分26(IQR 19-31)。
- 病因构成:肾前性AKI 44.3%,ATN 30.4%,HRS-AKI 12.1%,其他AKI 6.0%,无法分类7.2%。
- 8.1%的患者接受了肝移植,36.5%在90天内死亡。
- 90天死亡率肾前性AKI最低为22.2%(p<0.001),HRS-AKI与ATN分别为49.0%与52.7%(p=0.42)。
- 以肾前性AKI为参照,90天死亡校正sHR:HRS-AKI 2.78(95%CI 2.18-3.54,p<0.001),ATN 2.83(95%CI 2.36-3.41,p<0.001)。
关键数值与推荐
- 校正分析中,较高AKI分期和治疗未完全应答与90天死亡风险增加相关(p<0.001)。
临床怎么用
- 研究结果代表美国移植/三级中心的实践模式,可作为采用特利加压素之前的基线情况。
- 作者认为需要进一步优化HRS-AKI的血管收缩剂治疗和ATN的支持治疗。
局限性
- 研究结果为美国移植/三级中心的实践模式,可能限制其外推性。
- 作者指出需要进一步优化HRS-AKI的血管收缩剂治疗和ATN的支持治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Acute kidney injury (AKI) in cirrhosis is common and associated with high morbidity, but the incidence rates of different etiologies of AKI are not well described in the US. We compared incidence rates, practice patterns, and outcomes across etiologies of AKI in cirrhosis. METHODS: We performed a retrospective cohort study of 11 hospital networks, including consecutive adult patients admitted with AKI and cirrhosis in 2019. The etiology of AKI was adjudicated based on pre-specified clinical definitions (prerenal/hypovolemic AKI, hepatorenal syndrome [HRS-AKI], acute tubular necrosis [ATN], other). RESULTS: A total of 2,063 patients were included (median age 62 [IQR 54-69] years, 38.3% female, median MELD-Na score 26 [19-31]). The most common etiology was prerenal AKI (44.3%), followed by ATN (30.4%) and HRS-AKI (12.1%); 6.0% had other AKI, and 7.2% could not be classified. In our cohort, 8.1% of patients received a liver transplant and 36.5% died by 90 days. The lowest rate of death was observed in patients with prerenal AKI (22.2%; p <0.001), while death rates were higher but not significantly different from each other in those with HRS-AKI and ATN (49.0% vs. 52.7%; p = 0.42). Using prerenal AKI as a reference, the adjusted subdistribution hazard ratio (sHR) for 90-day mortality was higher for HRS-AKI (sHR 2.78; 95% CI 2.18-3.54; p <0.001) and ATN (sHR 2.83; 95% CI 2.36-3.41; p <0.001). In adjusted analysis, higher AKI stage and lack of complete response to treatment were associated with an increased risk of 90-day mortality (p <0.001 for all). CONCLUSION: AKI is a severe complication of cirrhosis. HRS-AKI is uncommon and is associated with similar outcomes to ATN. The etiology of AKI, AKI stage/severity, and non-response to treatment were associated with mortality. Further optimization of vasoconstrictors for HRS-AKI and supportive therapies for ATN are needed. IMPACT AND IMPLICATIONS: Acute kidney injury (AKI) in cirrhosis carries high morbidity, and management is determined by the etiology of injury. However, a large and well-adjudicated multicenter database from US centers that uses updated AKI definitions is lacking. Our findings demonstrate that acute tubular necrosis and hepatorenal syndrome have similar outcomes (∼50% mortality at 90 days), though hepatorenal syndrome is uncommon (12% of all AKI cases). These findings represent practice patterns at US transplant/tertiary centers and can be used as a baseline, presenting the situation prior to the adoption of terlipressin in the US.
引用
- Patidar KR, Belcher JM, Regner KR, et al. Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US. J Hepatol. 2023. PMID: 37517455. doi:10.1016/j.jhep.2023.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。